Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator

Study Questions:

What is the risk of symptomatic intracranial hemorrhage (sICH) among patients with ischemic stroke treated with intravenous tissue plasminogen activator (tPA) who were receiving warfarin versus those who were not, and degree of this risk as a function of international normalized ratio (INR)?